Angiogenesis in gastrointestinal stromal tumors: From bench to bedside

Papadakos, Stavros P.; Tsagkaris, Christos; Papadakis, Marios; Papazoglou, Αndreas S.; Moysidis, Dimitrios V.; Zografos, Constantinos G; Theocharis, Stamatios

doi:10.4251/wjgo.v14.i8.1469

Cited by 6 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor metastasis is associated with intricate interactions among primary tumor cells, encompassing activities such as invasion, intravasation, immune evasion, and extravasation from the circulatory system. Subsequent events include lymphangiogenesis/angiogenesis and migration towards specific target organs [ 61 ].…”

Section: Understanding Metformin’s Molecular Mechanisms In Ecmentioning

confidence: 99%

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

Papadakos,

Argyrou,

Lekakis

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Esophageal cancer (EC) remains a formidable malignancy with limited treatment options and high mortality rates, necessitating the exploration of innovative therapeutic avenues. Through a systematic analysis of a multitude of studies, we synthesize the diverse findings related to metformin’s influence on EC. This review comprehensively elucidates the intricate metabolic pathways and molecular mechanisms through which metformin may exert its anti-cancer effects. Key focus areas include its impact on insulin signaling, AMP-activated protein kinase (AMPK) activation, and the mTOR pathway, which collectively contribute to its role in mitigating esophageal cancer progression. This review critically examines the body of clinical and preclinical evidence surrounding the potential role of metformin, a widely prescribed anti-diabetic medication, in EC management. Our examination extends to the modulation of inflammation, oxidative stress and angiogenesis, revealing metformin’s potential as a metabolic intervention in esophageal cancer pathogenesis. By consolidating epidemiological and clinical data, we assess the evidence that supports metformin’s candidacy as an adjuvant therapy for esophageal cancer. By summarizing clinical and preclinical findings, our review aims to enhance our understanding of metformin’s role in EC management, potentially improving patient care and outcomes.

show abstract

Section: Understanding Metformin’s Molecular Mechanisms In Ecmentioning

confidence: 99%

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

Papadakos,

Argyrou,

Lekakis

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The molecular mechanisms of metastasis in HCC are complex and involve multiple processes such as epithelial–mesenchymal transition (EMT), by which epithelial cells lose their polarity and acquire a mesenchymal phenotype, allowing them to migrate and invade the surrounding tissues, angiogenesis [ 109 ], cell adhesion, proteases and immune evasion [ 110 ]. A recent study provided evidence that a five-gene signature related to EMT ( P3H1 , SPP1 , MMP1 , LGALS1 and ITGB5) could be a useful prognostic tool for HCC patients.…”

Section: Preclinical Evidence About Metformin Influence On Hcc Hallmarksmentioning

confidence: 99%

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?

Papadakos

Ferraro

Carbone

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. There has been significant progress in understanding the risk factors and epidemiology of HCC during the last few decades, resulting in efficient preventative, diagnostic and treatment strategies. Type 2 diabetes mellitus (T2DM) has been demonstrated to be a major risk factor for developing HCC. Metformin is a widely used hypoglycemic agent for patients with T2DM and has been shown to play a potentially beneficial role in improving the survival of patients with HCC. Experimental and clinical studies evaluating the outcomes of metformin as an antineoplastic drug in the setting of HCC were reviewed. Pre-clinical evidence suggests that metformin may enhance the antitumor effects of immune checkpoint inhibitors (ICIs) and reverse the effector T cells’ exhaustion. However, there is still limited clinical evidence regarding the efficacy of metformin in combination with ICIs for the treatment of HCC. We appraised and analyzed in vitro and animal studies that aimed to elucidate the mechanisms of action of metformin, as well as clinical studies that assessed its impact on the survival of HCC patients.

show abstract

“…It is an essential process for the growth and development of many normal tissues and organs, including the formation of blood vessels during embryonic development, wound healing, and the female reproductive cycle. However, angiogenesis can also play a critical role in the growth and spread of cancer [ 65 , 66 ]. There are several mechanisms that contribute to cancer angiogenesis including the release of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) from cancer cells, hypoxia, tumor-associated macrophages (TAMs), extracellular matrix remodeling, and tumor-associated endothelial cells (TECs) [ 65 , 67 , 68 ].…”

Section: The Eph/ephrin Signaling In Hcc—preclinical Datamentioning

confidence: 99%

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

Papadakos

Stergiou

Gkolemi

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Liver cancer is a complex and challenging disease with limited treatment options and dismal prognosis. Understanding the underlying molecular mechanisms driving liver cancer progression and metastasis is crucial for developing effective therapeutic strategies. The EPH/ephrin system, which comprises a family of cell surface receptors and their corresponding ligands, has been implicated in the pathogenesis of HCC. This review paper aims to provide an overview of the current understanding of the role of the EPH/ephrin system in HCC. Specifically, we discuss the dysregulation of EPH/ephrin signaling in HCC and its impact on various cellular processes, including cell proliferation, migration, and invasion. Overall, the EPH/ephrin signaling system emerges as a compelling and multifaceted player in liver cancer biology. Elucidating its precise mechanisms and understanding its implications in disease progression and therapeutic responses may pave the way for novel targeted therapies and personalized treatment approaches for liver cancer patients. Further research is warranted to unravel the full potential of the EPH/ephrin system in liver cancer and its clinical translation.

show abstract

Angiogenesis in gastrointestinal stromal tumors: From bench to bedside

Cited by 6 publications

References 67 publications

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

Contact Info

Product

Resources

About